Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022010666> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2022010666 endingPage "48" @default.
- W2022010666 startingPage "43" @default.
- W2022010666 abstract "Augmenter le taux de HDL-cholestérol par inhibition de la cholesteryl ester transfer protein (CETP) pour diminuer le risque cardiovasculaire résiduel sous statine est un concept remis en cause par l’échec du torcétrapib. De fait, même si la CETP favorise un profil athérogène des lipoprotéines par redistribution des esters de cholestérol des HDL vers les lipoprotéines contenant l’apoprotéine B (ApoB), ce transfert lipidique peut également avoir des propriétés antiathérogènes. Toutefois, des effets spécifiques du torcétrapib sur la pression artérielle, non liés à l’inhibition de la CETP, pourraient être à l’origine de l’échec de ce médicament. D’autres inhibiteurs de la CETP, tels que le dalcétrapib et l’anacétrapib, ne paraissent pas avoir d’effet délétère sur la pression artérielle. Mais, seuls les résultats des larges essais de prévention cardiovasculaire en cours pourront indiquer si, en plus de l’élévation du taux de HDL-cholestérol, l’inhibition de la CETP est un traitement valide en addition à une statine chez les patients à haut risque cardiovasculaire. The concept that HDL-cholesterol raising through inhibition of cholesteryl ester transfer protein (CETP) may decrease the residual cardiovascular risk observed on statin therapy has been challenged by the failure of the CETP inhibitor, torcetrapib. Indeed even if CETP contributes to an atherogenic lipoprotein profile by redistributing cholesteryl esters from HDL toward apoB containing lipoproteins, this lipid transfer may also have antiatherogenic properties. However, off-target effects of torcetrapib on blood pressure, unrelated to CETP inhibition, were believed to provide an explanation for the failure of this drug. Other CETP inhibitors, such as dalcetrapib and anacetrapib, are unlikely to increase blood pressure. Results of large ongoing clinical end-point trials are necessary to provide convincing evidence that, in addition to raising HDL-cholesterol, CETP inhibition is a viable strategy in addition to statin therapy in high-risk patients." @default.
- W2022010666 created "2016-06-24" @default.
- W2022010666 creator A5037200495 @default.
- W2022010666 date "2012-02-01" @default.
- W2022010666 modified "2023-09-27" @default.
- W2022010666 title "Les inhibiteurs de la CETP" @default.
- W2022010666 cites W1973740761 @default.
- W2022010666 cites W1976347559 @default.
- W2022010666 cites W1983281268 @default.
- W2022010666 cites W1995722781 @default.
- W2022010666 cites W2003803208 @default.
- W2022010666 cites W2014558113 @default.
- W2022010666 cites W2016936415 @default.
- W2022010666 cites W2031532845 @default.
- W2022010666 cites W2050026966 @default.
- W2022010666 cites W2090464684 @default.
- W2022010666 cites W2101777997 @default.
- W2022010666 cites W2102941237 @default.
- W2022010666 cites W2106624199 @default.
- W2022010666 cites W2108297214 @default.
- W2022010666 cites W2126666720 @default.
- W2022010666 cites W2134811220 @default.
- W2022010666 cites W2141210634 @default.
- W2022010666 cites W2151833491 @default.
- W2022010666 cites W2152683287 @default.
- W2022010666 cites W2158057499 @default.
- W2022010666 cites W2159243445 @default.
- W2022010666 cites W2164089346 @default.
- W2022010666 cites W2168210172 @default.
- W2022010666 doi "https://doi.org/10.1016/s1957-2557(12)70354-1" @default.
- W2022010666 hasPublicationYear "2012" @default.
- W2022010666 type Work @default.
- W2022010666 sameAs 2022010666 @default.
- W2022010666 citedByCount "0" @default.
- W2022010666 crossrefType "journal-article" @default.
- W2022010666 hasAuthorship W2022010666A5037200495 @default.
- W2022010666 hasConcept C134018914 @default.
- W2022010666 hasConcept C153911025 @default.
- W2022010666 hasConcept C185592680 @default.
- W2022010666 hasConcept C2778163477 @default.
- W2022010666 hasConcept C2780072125 @default.
- W2022010666 hasConcept C45505151 @default.
- W2022010666 hasConcept C62746215 @default.
- W2022010666 hasConcept C71924100 @default.
- W2022010666 hasConcept C86803240 @default.
- W2022010666 hasConceptScore W2022010666C134018914 @default.
- W2022010666 hasConceptScore W2022010666C153911025 @default.
- W2022010666 hasConceptScore W2022010666C185592680 @default.
- W2022010666 hasConceptScore W2022010666C2778163477 @default.
- W2022010666 hasConceptScore W2022010666C2780072125 @default.
- W2022010666 hasConceptScore W2022010666C45505151 @default.
- W2022010666 hasConceptScore W2022010666C62746215 @default.
- W2022010666 hasConceptScore W2022010666C71924100 @default.
- W2022010666 hasConceptScore W2022010666C86803240 @default.
- W2022010666 hasIssue "1" @default.
- W2022010666 hasLocation W20220106661 @default.
- W2022010666 hasOpenAccess W2022010666 @default.
- W2022010666 hasPrimaryLocation W20220106661 @default.
- W2022010666 hasRelatedWork W1973858093 @default.
- W2022010666 hasRelatedWork W2026316399 @default.
- W2022010666 hasRelatedWork W2048806202 @default.
- W2022010666 hasRelatedWork W2089360264 @default.
- W2022010666 hasRelatedWork W2092753298 @default.
- W2022010666 hasRelatedWork W2101272658 @default.
- W2022010666 hasRelatedWork W2103694711 @default.
- W2022010666 hasRelatedWork W2271298233 @default.
- W2022010666 hasRelatedWork W2282603121 @default.
- W2022010666 hasRelatedWork W3036866 @default.
- W2022010666 hasVolume "6" @default.
- W2022010666 isParatext "false" @default.
- W2022010666 isRetracted "false" @default.
- W2022010666 magId "2022010666" @default.
- W2022010666 workType "article" @default.